[Treatment Result of Neoadjuvant Endocrine Therapy in Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer in Our Hospital].

To date, neoadjuvant endocrine therapy has shown the same rate of clinical objective response and breast-conserving surgery as neoadjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer. Moreover, neoadjuvant endocrine therapy is recommended to the patients who are unable to tolerate side effects associated with chemotherapy or who are ineligible for immediate surgery because of their age and comorbidity. We discuss the result of neoadjuvant endocrine therapy in our hospital last 5 years.

[A Case of Drug-Induced Interstitial Lung Disease Associated with Epirubicin and Cyclophosphamide Therapy before Operation].

We report the case of a 60-year-old woman with right breast cancer. Approximately 18 years had passed since the treatment for left breast cancer without recurrence. She became aware of the right breast tumor with mild pain 5 months before she came to the hospital.

[A Case of Liver Failure Induced by Toremifene in a Patient with Metastatic Breast Cancer].

A 67-year-old woman underwent total mastectomy, postoperative radiation therapy, and adjuvant hormonal therapy more than 9 years 4 months previously. There were no symptoms of recurrence for 3.5 years after completing adjuvant hormonal therapy.

Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.

Purpose: Metronomic combination chemotherapy with the oral fluoropyrimidine doxifluridine/5'-deoxy-5-fluorouridine (5 -DFUR) and oral cyclophosphamide (C) showed promising efficacy in a single-arm study. The oral fluoropyrimidine capecitabine was designed to deliver 5-fluorouracil preferentially to tumors, potentially improving efficacy over doxifluridine. We conducted a phase II multicenter study to evaluate an all-oral XC combination in patients with HER2-negative metastatic breast cancer (MBC).